Literature DB >> 16786386

[Vertebroplasty in the treatment of back pain].

C G Trumm1, T F Jakobs, C J Zech, C Weber, M F Reiser, R-T Hoffmann.   

Abstract

BACKGROUND: Percutaneous vertebroplasty (PVP) represents a minimally invasive option which is gaining in importance for the treatment of vertebral compression fractures (VCF) and osteolysis of the spine. This article describes the indications for its use, peri-interventional imaging, technique, and results of PVP.
MATERIAL AND METHODS: The current guidelines for performance of PVP are explained in accordance with the "Interdisciplinary Consensus Paper on Vertebroplasty and Kyphoplasty" of the German Professional Associations and the 2005 CIRSE Guidelines. The results of our own study carried out in 2002 are compared to the complication rates and clinical outcomes reported in the literature.
RESULTS: Painful osteoporotic VCF and osteolysis within the vertebral body due to metastases and multiple myeloma are indications for PVP. Absolute contraindications are, in particular, asymptomatic VCF, alleviation of pain by drug treatment, therapy-refractory coagulopathies, allergies to cement components, and active infections. MRI or CT is indicated before undertaking PVP to assess the fracture age, to exclude other causes of pain, and to evaluate the posterior edge of the vertebral body. High-quality mono- or biplanar fluoroscopy--preferably in combination with CT (fluoroscopy)--is necessary for PVP to minimize the risk of cement leakage. A clear reduction in pain [mean reduction of 6.1 points (VAS)] is achieved in 86-92% of the patients with PVP. Our own study treating 58 patients (mean follow-up 323+/-99 days) revealed a clear alleviation of pain in 77% [-5.7 points (VAS)].
CONCLUSION: PVP constitutes a safe and effective minimally invasive treatment approach to stabilize and reduce acute and chronic back pain due to osteoporotic VCF and tumor-associated osteolysis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16786386     DOI: 10.1007/s00117-006-1382-7

Source DB:  PubMed          Journal:  Radiologe        ISSN: 0033-832X            Impact factor:   0.635


  37 in total

Review 1.  Percutaneous vertebroplasty: a developing standard of care for vertebral compression fractures.

Authors:  J M Mathis; J D Barr; S M Belkoff; M S Barr; M E Jensen; H Deramond
Journal:  AJNR Am J Neuroradiol       Date:  2001-02       Impact factor: 3.825

2.  [Guidelines of the German Radiological Society for percutaneous vertebroplasty].

Authors:  T Helmberger; K Bohndorf; J Hierholzer; G Nöldge; D Vorwerk
Journal:  Radiologe       Date:  2003-09       Impact factor: 0.635

3.  Percutaneous vertebroplasty: indications, technique, and results.

Authors:  Afshin Gangi; Stephane Guth; Jean Pierre Imbert; Horia Marin; Jean-Louis Dietemann
Journal:  Radiographics       Date:  2003 Mar-Apr       Impact factor: 5.333

4.  Percutaneous vertebroplasty and kyphoplasty in patients with multiple myeloma.

Authors:  Benedetta Bartolozzi; Chiara Nozzoli; Cesare Pandolfo; Elisabetta Antonioli; Giancarlo Guizzardi; Riccardo Morichi; Alberto Bosi
Journal:  Eur J Haematol       Date:  2006-02       Impact factor: 2.997

5.  Midterm outcome after vertebroplasty: predictive value of technical and patient-related factors.

Authors:  Juerg Hodler; Dallas Peck; Louis A Gilula
Journal:  Radiology       Date:  2003-04-17       Impact factor: 11.105

6.  Percutaneous polymethylmethacrylate vertebroplasty in the treatment of osteoporotic vertebral body compression fractures: technical aspects.

Authors:  M E Jensen; A J Evans; J M Mathis; D F Kallmes; H J Cloft; J E Dion
Journal:  AJNR Am J Neuroradiol       Date:  1997 Nov-Dec       Impact factor: 3.825

7.  Back pain, disability, and radiographic vertebral fracture in European women: a prospective study.

Authors:  T W O'Neill; W Cockerill; C Matthis; H H Raspe; M Lunt; C Cooper; D Banzer; J B Cannata; M Naves; B Felsch; D Felsenberg; J Janott; O Johnell; J A Kanis; G Kragl; A Lopes Vaz; G Lyritis; P Masaryk; G Poor; D M Reid; W Reisinger; C Scheidt-Nave; J J Stepan; C J Todd; A D Woolf; J Reeve; A J Silman
Journal:  Osteoporos Int       Date:  2004-05-12       Impact factor: 4.507

8.  Prospective evaluation of pain relief in 100 patients undergoing percutaneous vertebroplasty: results and follow-up.

Authors:  J Kevin McGraw; John A Lippert; Kirk D Minkus; Parag M Rami; Thomas M Davis; Ronald F Budzik
Journal:  J Vasc Interv Radiol       Date:  2002-09       Impact factor: 3.464

9.  Percutaneous vertebroplasty for osteolytic metastases and myeloma: effects of the percentage of lesion filling and the leakage of methyl methacrylate at clinical follow-up.

Authors:  A Cotten; F Dewatre; B Cortet; R Assaker; D Leblond; B Duquesnoy; P Chastanet; J Clarisse
Journal:  Radiology       Date:  1996-08       Impact factor: 11.105

10.  [Preliminary note on the treatment of vertebral angioma by percutaneous acrylic vertebroplasty].

Authors:  P Galibert; H Deramond; P Rosat; D Le Gars
Journal:  Neurochirurgie       Date:  1987       Impact factor: 1.553

View more
  4 in total

1.  Percutaneous vertebroplasty with the rotational fluoroscopy imaging technique.

Authors:  Alessandro Cannavale; Filippo Maria Salvatori; Andrea Wlderk; Carlo Cirelli; Alessandro d'Adamo; Fabrizio Fanelli
Journal:  Skeletal Radiol       Date:  2014-06-06       Impact factor: 2.199

2.  Mortality in the vertebroplasty population.

Authors:  R J McDonald; S J Achenbach; E J Atkinson; L A Gray; H J Cloft; L J Melton; D F Kallmes
Journal:  AJNR Am J Neuroradiol       Date:  2011-10-13       Impact factor: 3.825

3.  Vertebroplasty in the treatment of osteoporosis vertebral fractures: report on 52 cases.

Authors:  L Fenoglio; P Cena; E Migliore; C Bracco; D Ferrigno; A Silvestri; G Lingua; G Gollè; C Brignone; C Serraino; G Gallarato; F Pomero; M Grosso
Journal:  J Endocrinol Invest       Date:  2008-09       Impact factor: 4.256

4.  Vertebroplasty in multiple myeloma: outcomes in a large patient series.

Authors:  R J McDonald; A T Trout; L A Gray; A Dispenzieri; K R Thielen; D F Kallmes
Journal:  AJNR Am J Neuroradiol       Date:  2008-01-17       Impact factor: 3.825

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.